The U.S. Food and Drug Administration approved Amjevita, a drug similar to Humira, for use in the United States in 2016. This is a significant milestone for the pharmaceutical industry, as Amjevita is an important biosimilar to be approved in the United States. Biosimilars are drugs similar to existing biologic drugs and are expected to provide a more affordable option for patients. With the approval of Amjevita, the FDA has opened the door for more biosimilars to be approved in the future, potentially providing more affordable treatments for various diseases. This article will review all the details about these two drugs, including their similarities and differences. We’ll also talk about diseases they’re approved to treat, side effects, common myths, and the risks of taking these drugs during pregnancy. Read on to learn all this and more!